Real-time learning for the mobile generation

Using Clinicopathologic Markers in Patients with Non–Small-Cell Lung Cancer:
A Pathologist’s Perspective

This activity is presented by the Johns Hopkins University School of Medicine.

Supported by educational grants from Bristol-Myers Squibb Company, Genentech, Inc, and OSI Pharmaceuticals Inc.

Please click "enroll now" to begin course.

OVERVIEW
In the United States, lung cancer remains the leading cause of cancer mortality in both men and women, with more than 50% of patients presenting with locally advanced, inoperable, or metastatic disease. Approximately 33% of patients with non–small-cell lung cancer (NSCLC) present with advanced-stage disease while most patients with early stage NSCLC will eventually develop metastatic lung cancer. Despite the numerous therapeutic options available, only 15% of patients with lung cancer survive beyond 5 years from diagnosis. Recent advances in genetic and histological markers, coupled with emerging targeted agents for NSCLC, have the potential to improve patient outcomes. The following educational activity uses a series of case-based and knowledge questions to discuss the prognostic and predictive role of histologic and immunohistochemical markers in NSCLC therapy, the evaluation of current and emerging therapeutic strategies, and methods for recognizing how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC and improve outcomes.

GOAL
This educational activity will provide anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists, with up-to-date information about using clinicopathologic markers in patients with NSCLC.

INTENDED AUDIENCE
This activity is designed for anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists. No prerequisites required.

LEARNING OBJECTIVE
Upon the conclusion of this activity, the participant should be able to:

• Describe the prognostic and predictive role of histologic and immunohistochemical markers in NSCLC therapy.
• Evaluate current and emerging therapeutic strategies that incorporate targeted agents with chemotherapy for patients with advanced NSCLC based on tumor biology.
• Recognize how gene expression profiling and mutation analysis may help to customize therapy for patients with NSCLC.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Johns Hopkins University School of Medicine is a provider for Self-Assessment Modules as defined by the American Board of Pathology, and has designated this educational activity for a maximum of 2.0 SAM credits.

The estimated time to complete this activity: 2 hours.

Release date: August 15, 2011. Expiration date: August 15, 2012.

HOW TO RECEIVE CREDIT OR CONTACT HOURS
The following SpacedEd module consists of 20 questions that will be sent to you on a regular schedule via email, the Web, or RSS. They can be accessed from a desktop browser or a mobile device such as an iPhone or BlackBerry. The sequence of questions will adapt based on your answers. Questions are retired after 2 correct responses. All 20 questions must be retired to receive CME credit. A certificate of participation will be available online immediately following successful completion of the course.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Chair and Planner
Peter B. Illei, MD
Assistant Professor of Pathology
Director of Immunopathology Laboratory
Johns Hopkins Medical Institutions
Baltimore, Maryland

Participating Faculty/Authors
Andre Luis Moreira, MD, PhD (Planner)
Associate Attending Pathologist
Memorial Sloan-Kettering Cancer Center
New York, New York

Participating Faculty Disclosures
No speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentation(s).

Planner Disclosures
No planner has indicated that they have any financial interests or relationships with a commercial entity.

Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION
No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing names implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. CME at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Johns Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person’s health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/2000/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

This activity is designed for anatomic and clinical pathologists, including pulmonary pathologists and cytopathologists. No prerequisites required.